The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
AstraZeneca Pty Ltd
Regulatory activities for this sponsor.
Loading...
Sponsor content
321 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Tezspire, tezepelumab 210 mg in 1.91mL solution for Injection prefilled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Tezspire tezepelumab 210 mg in 1.91mL solution for Injection prefilled pen.
-
-
Prescription medicine registrationActive ingredients: trastuzumab deruxtecan.
-
-
Australian Public Assessment Report (AusPAR)Truqap (capivasertib), in combination with fulvestrant, was approved for the treatment of adult patients with hormone receptor positive, human epidermal growth factor receptor 2 negative, locally advanced or metastatic breast cancer following recurrence or progression on or after an endocrine-based regimen.
-
-
-
Jan-2025Prescription medicine evaluationActive ingredient: durvalumab.
-
Jan-2025Prescription medicine evaluationActive ingredient: acalabrutinib maleate monohydrate.